Clinical Trial Update: Alternative Dosing and Regimen of Replagal to Treat Fabry Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alternative dosing regimens of Replagal (agalsidase alfa) for Fabry disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Replagal (agalsidase alfa)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Fabry Disease | Phase 2 | Status: COMPLETED